An Olfactory 'stress Test' For The Early Detection Of Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$743,450.00
Summary
Early detection of Alzheimer's disease will be especially important when treatments become available that can slow or halt the progress of the disease. The sense of smell (olfaction) is affected early in the evolution of Alzheimer's disease. We have introduced a simple, inexpensive modification to standard testing of olfaction that we believe may help identify individuals with very early stage Alzheimer's disease. Our study is designed to assess this promising new approach.
Characterization Of A Novel Epigenetic Boundary And Long Range Epigenetic Modifications Specific To FMR1 Expansion Carriers With Behavioural And Cognitive Disorders - Implications For Earlier Diagnosis And Treatment.
Funder
National Health and Medical Research Council
Funding Amount
$670,836.00
Summary
Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability and autism and is caused by a faulty switch in the gene FMR1. We have discovered new DNA regions important in FXS. The project aims to explain how these new regions regulate the FMR1 gene. This is essential for the discovery and validation of new avenues for earlier diagnosis, treatments and therapies for children and adults with FMR1 disorders and also for informing reproductive decisions.
A Novel Multi-gene Marker Blood Test To Increase Community Participation In Colorectal Cancer Screening.
Funder
National Health and Medical Research Council
Funding Amount
$581,116.00
Summary
Bowel cancer screening programs are vital for early detection and prevention, but participation with the traditional faecal testing mode is less than 35%. Reasons include dislike or unsuitability for faecal testing. These barriers could be overcome and participation could increase using a different sampling mode for the screening test. We have developed a blood test for bowel cancer and will investigate if people who will not screen with the stool test will screen with the blood test instead.
Population Based Genetic Testing For High-risk Breast And Ovarian Cancer Predisposition Genes
Funder
National Health and Medical Research Council
Funding Amount
$1,112,985.00
Summary
Inherited mutations in BRCA1 and BRCA2 confer a very high risk of breast and ovarian cancer. Importantly, once carriers are identified, effective strategies are available that can dramatically reduce the risk of cancer. We will perform genetic testing of a healthy western population to identify breast/ovarian cancer genes before the women develop cancer. Population-based screening could significantly reduce the incidence of these diseases.
Identification And Characterisation Of Novel FLT3-ITD Co-operating Mutations
Funder
National Health and Medical Research Council
Funding Amount
$659,245.00
Summary
Acute myeloid leukaemia is a cancer of the blood and bone marrow. We have identified new genes that act with the known oncogene FLT3-ITD in myeloid disease. We will examine in detail how these new genes contribute to the development of AML. This will aid in the development of new therapies for groups of AML patients with these mutations.
AusGo-SHEMO….Let’s Go! Australian Gold Standard Health Economics Model Of Osteoporosis
Funder
National Health and Medical Research Council
Funding Amount
$378,959.00
Summary
We will develop an unbiased, gold standard, validated, transparent health economics model of osteoporosis to identify cost-effective screening and treatment strategies, and that will be made widely available to all stakeholders. Without this model, scarce health care resources may be squandered on osteoporosis screening strategies and osteoporosis-related fracture prevention medications that are not cost-effective. Worse, patient access to cost-effective medications may be delayed.
Optimising Men’s Uptake Of FIT Screening For Bowel Cancer: A Population Based Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$552,522.00
Summary
Men are more likely to die from bowel cancer but are not participating in the National Bowel Cancer Screening program to the same extent as women. The research group has devised simple messages that their previous research shows encourages men to use the screening kit. The team will compare the use of kits among men who get the Government’s usual invitations, with a group who receive invitations with the messages for men.
Circulating Tumour DNA (ctDNA) As A Diagnostic Tool In Colorectal Cancer: Role In Screening And Early Detection Of Metastatic Or Recurrent Disease
Funder
National Health and Medical Research Council
Funding Amount
$500,478.00
Summary
These studies will be exploring the value of using a blood test to detect cancer DNA as a screening test for colorectal cancer. This test promises to be superior to faecal blood testing, which is currently performed as part of the National Bowel Cancer Screening Program. It may also have advantages over colonoscopy as a screening tool. Given the likely acceptability of having a blood based screening test, it is expected that participation rates in bowel cancer screening, which has been shown to ....These studies will be exploring the value of using a blood test to detect cancer DNA as a screening test for colorectal cancer. This test promises to be superior to faecal blood testing, which is currently performed as part of the National Bowel Cancer Screening Program. It may also have advantages over colonoscopy as a screening tool. Given the likely acceptability of having a blood based screening test, it is expected that participation rates in bowel cancer screening, which has been shown to save lives, will be greatly increased.Read moreRead less
Non-invasive Retinal Vein Pulsation Pressure Measurement: A New Assessment Of Glaucoma Treatment.
Funder
National Health and Medical Research Council
Funding Amount
$557,666.00
Summary
Glaucoma is the second most common cause of blindness. It is a slowly degenerating disease and the level of treatment required is difficult to predict. At present there is no way of knowing whether the eye is receiving inadequate treatment. We have shown that retinal vein pulsation pressure measurements are an indicator of the likelihood of glaucoma progression. Our proposed studies hope to demonstrate for the first time that it is feasible to determine the appropriate treatment level for indivi ....Glaucoma is the second most common cause of blindness. It is a slowly degenerating disease and the level of treatment required is difficult to predict. At present there is no way of knowing whether the eye is receiving inadequate treatment. We have shown that retinal vein pulsation pressure measurements are an indicator of the likelihood of glaucoma progression. Our proposed studies hope to demonstrate for the first time that it is feasible to determine the appropriate treatment level for individual patients.Read moreRead less
Risks And Benefits Of Breast Cancer Screening: BreastScreen WA Cohort Study Of Overdiagnosis And Breast Cancer Mortality
Funder
National Health and Medical Research Council
Funding Amount
$201,524.00
Summary
Overdiagnosis is the major downside of screening for breast cancer. This occurs when screening detects cancers that would not have caused symptoms in the woman's lifetime. This study aims to quantify the amount of overdiagnosis that occurs in the Australian breast cancer screening program (BreastScreen)